The general trend of mergers and acquisitions in the pharmaceutical industry is obvious, and pharmaceutical companies are speeding up their running.

Pharmaceutical Network Industry Dynamics: On July 27, Dongcheng Pharmaceuticals announced that its wholly-owned subsidiary Andico will acquire a 48.3084% stake in Meddo Bio (corresponding to a registered capital of 949.37 million yuan) for 96.65 million yuan in cash.medo bio is the leading domestic molecular imaging pharmaceutical research and development outsourcing (MI-CRO) enterprises, for customers at home and abroad to provide drug screening, biological distribution, pharmacokinetics research, pharmacodynamics evaluation and other new drug research and development solutions and outsourcing technical services.financial data show that in 2019 and the first quarter of 2020, Medu Bio achieved revenue of RMB19,057.3 million and RMB2,910.9 million, respectively, with net profit of RMB839.7 million and -1.9134 million yuan.Dongcheng Pharmaceuticals said that the acquisition of the company based on strategic planning and operational development needs, the acquisition of a portion of the equity of Medo bio, using its characteristic tracetechnolog in molecular imaging technology advantages, accurate quantitative and qualitative determination of the target accuracy of new drugs and drug effectiveness, for the company's innovative drug decision-making and research pipeline strategic planning to lay the foundation. At the same time, the, the use of milu biology in the nuclear drug conversion resources and experience, for the company's nuclear drugs in the research of new drugs to provide a one-stop CRO service, further promote the company in the research of new drug conversion efficiency, accelerate the speed of new drugs to enter the market.in fact, the industry's pharmaceutical mergers and acquisitions of the general trend has become more obvious.since July, in addition to Dongcheng Pharmaceuticals, The Same Pharmaceuticals, Sanli Pharmaceuticals, Haizheng Pharmaceuticals, Merya, Guangshengtang and other pharmaceutical companies have issued mergerand announcements.for example, The National Pharmaceutical Industry unanimously announced on July 21 stilettos that it intends to publicly delist the regional large pharmaceutical circulation enterprises into a large square 100% equity, publiclisting transfer floor price of 1.86 billion yuan. On July 20,, Guizhou Sanli Pharmaceuticals announced that it intends to increase its capital to Guizhou Hanfang Pharmaceutical Co., Ltd. and Guiyang Dechangxiang Pharmaceutical Co., Ltd. in cash to acquire no more than 51% of the shares of Hanfang Pharmaceuticals and Dechangxiang PharmaceuticalCoa.Sanli Pharmaceuticals intends to pay a deposit of RMB 100 million to the asset controller. Haizheng Pharmaceuticals, whichlost money in the first quarter of this year, recently announced plans to acquire a 49% stake in Hanyu Pharmaceuticals, which is tentatively priced at 4.337 billion to 4.484 billion yuan.the acquisition is completed, Haizheng Pharmaceuticals will hold a full stake in the latter.for fy2018, 2019 and January-March 2020 (unaudited), Hanyu Pharmaceuticals' net profit attributable to the owners of the parent company was RMB529 million, RMB541 million and RMB255 million (unaudited), respectively.with the completion of the acquisition, Hanyu Pharmaceuticals may be expected to significantly improve The performance of Haizheng Pharmaceuticals.Jinshi Ya Pharmaceuticals also announced that the company signed an "equity acquisition intention agreement" with Jiangxi Jurentang Pharmaceutical Co., Ltd. on July 15, to acquire 100% of the shares in Jurentang in cash, with an estimated equity value of 93 million yuan.Said that the proposed acquisition of Jurentang equity in the company's pharmaceutical large health product line, improve the company's competitiveness and profitability in the field of pharmaceutical health, in line with the company's development strategy. , in addition, from some pharmaceutical companies such as Dongcheng Pharmaceuticals merger and acquisition purposes can be clearly seen, its focus in the accelerated shift to innovative drugs. the future, the innovative drug market will usher in more vitality. industry pointed out that in the volume of procurement normalization, generic drug consistency evaluation and other policies, the trend of health insurance funds caged for birds has been formed, more and more innovative drugs are included in it, in this context, domestic pharmaceutical companies are also increasing investment in innovative research and development, through acquisitions and other ways in-depth layout. .